Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies
Authors:
- 3 April 2018
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 108 (2) , 184-191
Abstract
Febrile neutropenia (FN) is often observed in hematological malignancies (HEM). Presepsin is also known as soluble CD14 subtype; it is a glycoprotein fragment derived from monocytes and macrophages. We aimed to evaluate the significance of presepsin and other biomarkers for diagnosis of bacteremia in children with HEM. Sixty pediatric patients with different HEM (acute lymphoblastic leukemia 36, acute myeloid leukemia 12, non-Hodgkin lymphoma 10, and Hodgkin disease 2). Thirty age and sex-matched healthy children serving as control were enrolled in this study. Estimation of presepsin, procalcitonin (PCT), and C-reactive protein (CRP) during episode of FN in addition to absolute neutrophils count (ANC) and blood culture was performed for all the participants. Presepsin levels were higher in the patients than in control with a higher increments in the positive blood cultures than the sterile cases. Presepsin concentration was significantly higher in bacteremia than clinically proved infection and fever of unknown origin. A statistically significant positive correlation between presepsin and CRP plus PCT levels but negative correlation with ANC were observed in the patients subgroups. Presepsin is a useful marker for detection of bacteremia with sensitivity and specificity (100 and 85.7%). This finding supported that presepsin was superior to PCT and CRP in identifying bacterial infection in FN.Keywords
This publication has 26 references indexed in Scilit:
- Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trialCritical Care, 2014
- Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective studyCritical Care, 2013
- The Usefulness of Procalcitonin and C-Reactive Protein as Early Diagnostic Markers of Bacteremia in Cancer Patients with Febrile NeutropeniaCancer Research and Treatment, 2011
- Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Management of Oral Mucositis in Patients Who Have CancerDental Clinics of North America, 2008
- A Prospective Study on the Epidemiology of Febrile Episodes during Chemotherapy-Induced Neutropenia in Children with Cancer or after Hemopoietic Stem Cell TransplantationClinical Infectious Diseases, 2007
- Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysisCritical Care Medicine, 2006
- Infections in Patients with Febrile Neutropenia: Epidemiology, Microbiology, and Risk StratificationClinical Infectious Diseases, 2005
- Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropeniaCancer, 2004
- Value of measurement of C-reactive protein in febrile patients with hematological malignanciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992